期刊文献+

脑胶质瘤的综合临床治疗的研究进展 被引量:16

下载PDF
导出
摘要 脑胶质瘤占颅内肿瘤的50.26%~60.96%(平均44.69%1,其发病危险因素尚不明确。低级别胶质瘤(wHOI、Ⅱ级)的中位生存时间为5~8年;高级别胶质瘤(WHOIU、IV级)称为恶性胶质瘤,Ⅲ级星形胶质细胞瘤的中位生存时间为3年;IV级的中位生存时间仅12。18个月,年龄大于60岁的患者生存时间更短[1,2]。高级别胶质瘤患者多在治疗后数月复发,治疗上采用综合疗法,包括手术切除、放射治疗及化学治疗等,但疗效仍难以令人满意。
作者 林婷婷 李钢
出处 《中国临床神经外科杂志》 2013年第5期316-319,共4页 Chinese Journal of Clinical Neurosurgery
基金 海南省自然科学基金(309108)
  • 相关文献

参考文献23

  • 1Li B, Zhao G, Cheng P, et al. The accuracy of survival time predicton for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression [J]. PloS One, 2011, 6(10): e25631.
  • 2Gladson CL, Prayson RA, Liu W. The pathobiology of glioma tumors [J]. Annu Rev Pathol, 2010, 5: 30-55.
  • 3Doblas S, He T, Saunders D, et al. Glioma morphology and tumor-induced vascular alterations revealed in 7 rodent glioma models by in vivo magnetic resonance imaging and angiography [J]. J Magn Reson Imaging, 2010, 32(2): 267- 275.
  • 4陈运洪.脑胶质瘤术中超声的基础及临床应用研究[J].南方医科大学学报,2008,18(23):132-138.
  • 5Shirai K, Suzuki Y, Okamoto M, et al. Influence of histologi- cal subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma [J]. J Radiat Res, 2010, 51(5): 589-594.
  • 6傅相平,李安民,张志文,赵明,易林华,闫润民,刘爱军.脑胶质瘤瘤旁近距离放疗临床研究[J].临床军医杂志,2010,38(6):913-915. 被引量:1
  • 7Frevschlag CF, Smolczyk DR, Janen E, et al. Prolonged ad- ministration of temozolomide in adult patients with anaplas- tic glioma [J]. Anticancer Res, 2011, 31(11): 3873-3877.
  • 8Riina HA, Knopman J, Greenfield JP, et al. Balloon- assisted superselective intra-arterial cerebral infusion of Bevacizumab for malignant brainstem glioma [J]. Intervl Neuroradiol, 2010, 16(1):71-76.
  • 9Chen KS, Mitchell DA. Monoclonal antibody therapy for malignant glioma [J]. Adv Exp Med Biol, 2012, 746: 121- 141.
  • 10Sen E. Targeting inflammation-induced transcription activtion: an open frontier for glioma therapy [J] Discov Today, 2011, 16(23-24): 1044-1051.

二级参考文献20

  • 1Salvati M, D'Elia A, Formichella AI,et al. Insights into pharmacotherapy of malignant glioma in adults [ J ]. Expert Opin Pharmacother, 2009, 10(14) :2279 -2290.
  • 2Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas[J]. Curr Oncol Rep, 2010,12 ( 1 ) :26 - 33.
  • 3Pichler J, Marosi C. Drug therapy of patients with recurrent glioblastoma: is there any evidence? [J]. Wien Med Wochenschr, 2011, 161(1-2) :26-31.
  • 4Brastianos PK, Batchelor TT. Vascular endothelial growth factor inhibitors in malignant gliomas [J]. Target Ontol,2010,5 ( 3 ) : 167 - 174.
  • 5Maiuri F, Del Basso De Caro M, Siciliano A, et al. Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival [J]. Clin Neuropathol, 2010, 29 ( 2 ) : 109 - 114.
  • 6Chang SM, Theodosopoulos P,Lamborn K, et al. Temnzolomidc in the treatment of recurrent malignant glioma[J]. Cancer, 2004, 100(3) : 605 -611.
  • 7Lashford LS, Thiesse P, Jouvet A, et al. Temozolemidc in malignant gliomas of childhood: a United Kingdom Children's Caneer Study Group and French Society for Pediatrie Ontology Intergroup Study[J]. J Clin Oncol, 2002, 20(24) : 4684 -4691.
  • 8Van Meter ME, Kim ES. Bevaeizumab: current updates in treatment[J]. Curr Opin Oncol,2010, 22(6) :586 -591.
  • 9Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas [ J ]. Cancer, 2010,116 ( 17 ) :3988 - 3999.
  • 10Hofer S, Elandt K, Greil R, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials [ J ]. Acta Oncol,2011,50 ( 5 ) :630 - 635.

共引文献13

同被引文献146

引证文献16

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部